Value of phosphodiesterase 5 inhibitors as a combination therapy for treating erectile dysfunction: A literature review

Abstract

Erectile dysfunction (ED) is increasing in prevalence, with estimates that 50% of men between 40 and 70 years of age suffer from the disease. Due to a wide array of available medical interventions, significant focus has been put on combination therapies that can treat ED refractory to first-line treatments such as phosphodiesterase 5 inhibitors (PDE5is). However, reviews evaluating monotherapy noninferiority and patient satisfaction of monotherapy versus combination therapy are lacking. A thorough PubMed search was performed to evaluate combination therapy in ED treatment. Articles published between January 2008 and June 2023 were reviewed, including randomized control trials, retrospective analyses, and cohort studies. Combination therapies included PDE5i plus another PDE5i, testosterone supplementation, α-blockers, vacuum erectile devices, intracavernosal injections, and low-intensity shockwave therapy. Based on this review, PDE5i monotherapy is not inferior to combination therapy and has increased satisfaction, convenience, and ease of use for patients with ED. Limitations of current literature on combination therapy include small sample size, limited data on patient satisfaction, possible biases, and limited follow-up time. Further studies will need larger randomized control trials with follow-up times greater than 1 year.

Keywords

combination therapy / erectile dysfunction / intracavernosal injection / low-intensity shockwave therapy / phosphodiesterase 5 inhibitor / vacuum erectile device

RIGHTS & PERMISSIONS

2024 2024 The Authors. UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.